ストックスクリーナーアプリを入手
0.0002
9,900%
0.0003
Vaxxinity Inc (VAXX) 最新ニュース
Critical Review: iBio (NYSE:IBIO) versus Vaxxinity (NASDAQ:VAXX) - Defense World
VAXX stock at $0.0001 intraday on 11 Feb 2026: critical risks for NASDAQ holders - Meyka
VAXX Vaxxinity, Inc. drops 99% to $0.0001 on NASDAQ 19 Jan 2026: outlook - Meyka
Analyzing Vaxxinity (NASDAQ:VAXX) and ProMetic Life Sciences (OTCMKTS:PFSCF) - Defense World
Vaxxinity Shares Plummet Amid Extreme Volatility - AD HOC NEWS
Analyzing Vaxxinity (NASDAQ:VAXX) & Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Tangible book value per share of Vaxxinity, Inc. – OTC:VAXX - TradingView
Hypercholesterolemia Pipeline Drugs Report 2025: MOA, Emerging Therapies, Clinical Trials, Treatment | DelveInsight - Barchart.com
Space Medicine Market Report 2025 | Innovative Space-Based Regenerative Medicine Aims to Enhance Human Health During Long-Duration Missions - 24matins.uk
Hypercholesterolemia Pipeline 2025: Innovative Clinical Advancements by 25+ Global Leaders – DelveInsight | Featuring companies such as Jiangsu HengRui Medicine Co., Ltd., Merck Sharp & Dohme LLC, Arr - Barchart.com
Dallas District Court Split in High-Stakes Stock Dispute - Inforney News
Migraine Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored | GlaxoSmithKline, Merck & Co., Inc., Pfizer, Bausch Health, Amgen, Abbvie Inc., AstraZeneca, Eli Lilly and Co - Barchart.com
Safety and immunogenicity of UB-612 heterologous booster in adults primed with mRNA, adenovirus, or inactivated COVID-19 vaccines: a randomized, active-controlled, Phase 3 trial - The Lancet
Top 6 Healthcare Stock Picks in 2025 - timothysykes.com
PCSK9 Inhibitors Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Statistics, Revenue, Pipeline, Therapies, and Companies by DelveInsight - The Globe and Mail
🐾 Pet of the Week: Meet Benny — Forney’s Frisbee-Loving Best Friend - Inforney News
Vaccinex plans Nasdaq exit as Alzheimer market pressure grows - Pharmaceutical Technology
How a new kind of vaccine could lead to the eradication of Alzheimer's and dementia - New Scientist
Vaxxinity - The Pharma Letter
Study: Therapeutic Parkinson's vaccine safely inhibits alpha-synuclein clumps - Parkinson's News Today
A Potential Parkinson’s Treatment Has Promising Results - Time Magazine
Parkinson's Prevention May Include Tetanus Vaccination - Vax-Before-Travel
Vaxxinity’s Immunotherapy Meets Phase I Goals in Parkinson’s Patients - Inside Precision Medicine
Vaxxinity UB-312 Parkinson’s Trial Results Published in Nature Medicine - Yahoo Finance
Vaxxinity leaders detail retreat from 'abusive relationship' after 3 years on public market - Fierce Biotech
VAXX Stock Price and Chart — OTC:VAXX - TradingView
Terrell Breaks Ground On Northspur Development - Inforney News
Vaxxinity, Inc. (VAXX) Perplexes All, Surges 44% Amidst Delisting Decision - 富途牛牛
Why Is Vaxxinity (VAXX) Stock Up 39% Today? - InvestorPlace
What's Driving These Stocks Higher In After-hours? - RTTNews
Why Is Vaxxinity (VAXX) Stock Down 58% Today? - TradingView
Vaxxinity to voluntarily delist from Nasdaq - Investing.com
Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting - GlobeNewswire
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates - Yahoo Finance
Parkinson's Drug Reduces Disease Markers in Breakthrough Trial - ScienceAlert
AD/PD 2024: Vaxxinity reveals Phase I success with Parkinson’s vaccine - Pharmaceutical Technology
Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024 - Yahoo Finance
Peek inside the Space Coast vaccine lab working to create humanity’s moonshot - WFTV
Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published - Yahoo Finance
Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024 - GlobeNewswire
Vaxxinity, University of Florida join for work on Parkinson’s vaccine - Parkinson's News Today
Scrip Asks…What Does 2024 Hold For Biopharma? Part 4: Transformative Technology - Citeline News & Insights
Vaxxinity, University of Central Florida launch collaboration to advance medicines for use in space - Fierce Biotech
Vaccines show promise against common chronic diseases - Gavi, the Vaccine Alliance
Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference - Stock Titan
Vaxxinity making vaccines to change the world - Labiotech.eu
Vaxxinity, Inc. (VAXX) stock price, news, quote and history - Yahoo Finance Singapore
Researchers return to Alzheimer's vaccines, buoyed by recent drug success - Reuters
Vaxxinity earnings missed by $9.89, revenue fell short of estimates - Investing.com UK
Mei Mei Hu - The World Economic Forum
Area fire departments fighting large grass fire north of Forney - Inforney News
Private companies invested in Vaxxinity, Inc. (NASDAQ:VAXX) copped the brunt of last week's US$41m market cap decline - Yahoo Finance
Fast-Tracked Alzheimer’s Vaccine Seems to Work, But Phase 3 Trials Stalled - Being Patient
Molina Rene Paula Net Worth (2025) - GuruFocus
Vaxxinity publishes positive results in Alzheimer’s trial - Longevity.Technology
Innovative Alzheimer's Disease Vaccine Candidate Can Add Value - Vax-Before-Travel
Anti-amyloid drug shows significant immune response in adults with mild Alzheimer’s - Healio
Vaxxinity Announces Publication of UB-311 Safety, - GlobeNewswire
Vaxxinity Reports Second Quarter 2023 Financial Results and Provides Corporate Update - GlobeNewswire
Vaxxinity Appoints Dr. Peter Powchik as Global Scientific Director - Yahoo Finance
Vaxxinity Appoints Peter Powchik, M.D., to EVP, Global Scientific Director - citybiz
Parkinson’s Patients Treatment Posts Positive Engagement - Vax-Before-Travel
Vaxxinity Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinson’s Patients - Yahoo Finance
Michael J. Fox Foundation Funds Parkinson’s Disease Vaccine Candidate - Vax-Before-Travel
Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson's Disease - Florida Hospital News and Healthcare Report
Vaxxinity celebrates trial success in early Parkinson’s therapy - Clinical Trials Arena
Two biotechs launch public offerings; Vaxxinity shares safety data on its Parkinson’s vaccine - Endpoints News
Vaxxinity shares update about potential vaccine UB-312 - Parkinson's News Today
Details Behind Potential Phase 2 Trial With UB-312 Alpha Synuclein Vaccine for Parkinson Disease - NeurologyLive
Vaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate Update - GlobeNewswire
Vaxxinity, Inc. (VAXX) Stock Forecast & Price Prediction 2025–2030 - CoinCodex
VXX-301, a tau vaccine with optimized properties - BioWorld MedTech
Upcoming Events - FinancialContent
Help wanted: Vaxxinity seeks a partner to press ahead with Alzheimer's treatment - Fierce Biotech
Clinical Trial of Investigational Vaccine to Treat LDL Cholesterol Underway - Diagnostic and Interventional Cardiology
Longevity investment bulletin: Vaxxinity, Aviceda, MyMD and more - longevity.technology
Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of VXX-401, Investigational Anti-PCSK9 Vaccine to Treat Hypercholesterolemia - Yahoo Finance
1.19%
大文字化:
|
ボリューム (24 時間):